Mirror 365 - NEWS THAT MATTERS

Dear Friends, Mirror365 launches new logo animation for its web identity. Please view, LIKE and share. Best Regards www.mirror365.com

Posted by Surinder Verma on Wednesday, June 17, 2020

PGI endocrinologists recognized for excellence at ENDO-2024 conference in Boston, USA

0
90

PGI endocrinologists recognized for excellence at ENDO-2024 conference in Boston, USA

Prof. Sanjay K. Bhadada wins prestigious Laureate Award for outstanding mentorship

Doctors from PGIMER, Chandigarh were recently awarded for their research at the recently conducted annual meeting and conference of the Endocrine Society, US (ENDO 2024). The conference was held at Boston, US in June 2024 and was attended by over 6000 endocrinologists, physicians and fellows from all over the globe. Prof. Sanjay K Bhadada, Head, Department of Endocrinology, was conferred the prestigious Laureate award honouring him as the Outstanding Mentor, being nominated by Prof. S Bhasin from Brigham and Women’s Hospital, Harvard University for his exceptional contribution to research and mentorship in metabolic bone disease including primary hyperparathyroidism, osteoporosis and rare bone diseases. He was additionally invited to represent India at the Global endocrinology leaders meeting and discuss the unique challenges affecting endocrinology in our country. Prof. Bhadada presented novel research work on bone health and microarchitecture with the use of sodium-dependent glucose cotransporters (SGLT2i) in postmenopausal women with type 2 diabetes mellitus, which was selected for oral presentation. Dr Bhadada recently also received Prof Maria Lusia Bianchi award at 51st European Calcified Tissue Society annual meeting held at Marseille France (May 2024)for his work on “insights from rare metabolic bone disease registry”

Dr. Liza Das was endowed with the Young investigator award at the conference meeting. This was in recognition of research work in pituitary disorders in the young faculty category. She presented a paper on the effects of oral glucagon-like peptide 1 (GLP1) analogue on metabolic-dysfunction associated steatotic liver disease (MASLD), erstwhile termed non-alcoholic fatty liver disease (NAFLD) and bone microarchitecture, in patients with type 2 diabetes mellitus and obesity in the meeting. She had earlier won the Early career investigator prize in pituitary disease last year at the 18thannual Pituitary congress, in Chicago. This was for her work assessing long-term cardiac and liver complications in patients with pituitary insufficiency (hypopituitarism) due to Sheehan’s syndrome, an uncommon cause of hypopituitarism in our settings.